

Freedom of Information Request

Ref: 22-132

28 March 2022

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:

- Carboplatin (monotherapy or in combination with 5-FU) *
- Cisplatin (monotherapy or in combination with 5-FU) 19
- Cetuximab with/without chemotherapy *
- Cetuximab with radiotherapy 0
- Pembrolizumab monotherapy 6
- Pembrolizumab with chemotherapy 0
- Nivolumab *
- Docetaxel (monotherapy or in combination with 5-FU) *
- Fluorouracil (5FU) 0
- Radiotherapy only 12
- Other *

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

- Total number of head and neck cancer patients
45
- Number of locally advanced head and neck cancer patients

Unable to say as the system does not differentiate in this way.

• **Number of recurrent and/or metastatic head and neck cancer patients**

Unable to say as the system does not differentiate in this way.

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

- **Atezolizumab** - 6
- **Carboplatin with Gemcitabine** - *
- **Carboplatin single or in any other combination** 0
- **Cisplatin with Gemcitabine** 9
- **Cisplatin single or in any other combination** 0
- **Nivolumab** - *
- **Pembrolizumab** - *
- **Any other regimen including Paclitaxel** - 7
- **Any other chemotherapy regimen** 8
- **Other active systemic anti-cancer therapy [please state] Avelumab** 10
- **Palliative care only**

The palliative care team have advised that they are unable to supply this data due to the vast number of ways patients can be referred to palliative care services, some of which bypass UHBW entirely.

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Thor study *

Atlantis *

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust